Compositions and methods for using genetically modified enzymes
AssigneeRenew Biopharma, Inc.
InventorsMichael Mendez, Joseph Noel, Michael Burkart, Jeremy Lanoiselee, Kyle Botsch, Matthew Saunders
Life of this patent
Estimating the term…
Abstract
The disclosure relates to the biosynthesis of cannabinoids and related prenylated phenolic compounds using recombinant enzymes. In particular, the disclosure provides recombinant mutant ORF2 enzymes engineered to produce a greater amount of a desired product, or to have a greater ability to catalyze a reaction using a desired substrate, as compared to WT ORF2. The disclosure also provides methods of preparing such ORF2 mutant enzymes; as well as methods of use thereof in improving the biosynthesis of cannabinoids and related prenylated phenolic compounds.
Claims26
A recombinant polypeptide comprising an amino acid sequence with at least 95% identity to SEQ ID NO:
- 1, wherein said amino acid sequence comprises an amino acid substitution to SEQ ID NO:
- 1 selected from the group consisting of Q161H, Q161Y, Q161R, Q161F, Q161L, Q161S, Q161T, Q161I, Q161M, Q295, S214, and Y288, wherein said recombinant polypeptide converts olivetolic acid (OA) and geranyl diphosphate (GPP) to cannabigerolic acid (CBGA) and 5-geranyl olivetolate (5-GOA), and wherein said recombinant polypeptide has a CBGA production potential that is higher than wild-type ORF2 enzyme under the same condition.
Dependencies are inferred from the claim text.